XML 37 R23.htm IDEA: XBRL DOCUMENT
v3.24.3

LOSS PER SHARE | 9 Months Ended
--- | ---
Sep. 30, 2024
Earnings Per Share [Abstract] |
LOSS PER SHARE | LOSS PER SHARE Loss per share attributable to Bausch Health Companies Inc. is calculated as follows:
| Three Months Ended September 30, |  | Nine Months Ended September 30,
(in millions, except per share amounts) | 2024 |  | 2023 |  | 2024 |  | 2023
Net loss attributable to Bausch Health Companies Inc. | $ | (85) |  |  | $ | (378) |  |  | $ | (139) |  |  | $ | (553) |
Basic and diluted weighted-average common shares outstanding | 368.4 |  |  | 365.4 |  |  | 367.7 |  |  | 364.5 |
Basic and diluted loss per share attributable to Bausch Health Companies Inc. | $ | (0.23) |  |  | $ | (1.03) |  |  | $ | (0.38) |  |  | $ | (1.52) |
During the three and nine months ended September 30, 2024 and 2023, all potential common shares issuable for stock options and RSUs were excluded from the calculation of diluted loss per share, as the effect of including them would have been anti-dilutive. The dilutive effect of potential common shares issuable for stock options and RSUs on the weighted-average number of common shares outstanding would have been approximately 2,245,000 and 2,656,000 common shares for the three and nine months ended September 30, 2024, respectively, and approximately 3,075,000 and 2,931,000 common shares for the three and nine months ended September 30, 2023, respectively. During the three and nine months ended September 30, 2024, time-based RSUs, performance-based RSUs and stock options to purchase approximately 14,554,000 and 14,416,000 common shares, respectively, were not included in the computation of diluted earnings per share because the effect would have been anti-dilutive under the treasury stock method. During the three and nine months ended September 30, 2023, time-based RSUs, performance-based RSUs and stock options to purchase approximately 12,268,000 and 12,387,000 common shares, respectively, were not included in the computation of diluted earnings per share because the effect would have been anti-dilutive under the treasury stock method. During each of the three and nine months ended September 30, 2023, 637,000 performance-based RSUs were not included in the computation of diluted earnings per share as the required performance conditions had not been met.

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContent Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration